subject: Capital Blitz Drug Development Outsourcing Companies Take The Opportunity To Upgrade [print this page] August 9, Wuxi PharmaTech successfully landing the NYSE, which is created following the traditional Chinese medicine in Guizhou Tongjitang the first registration NYSE stocks, China has created a precedent for overseas listing of domestic pharmaceutical companies. However, this time based on R & D outsourcing company's image appears.
WuXi PharmaTech's successful listing, the domestic pharmaceutical R & D outsourcing corporate finance has opened up a new path. "Capital is now more sought after this service R & D enterprise, and essentially chasing companies to invest." August 15, foolproof technology medicine Guo Xia president told reporters. New channels of financing
CRO The landing NYSE, the company is issuing nearly 1,320 shares of American Depository Receipts (ADR), priced at 14 dollars per share, the funds raised 184 million U.S. dollars.
WuXi PharmaTech's successful listing caused concern to the industry, the same company after the listing WuXi PharmaTech development planning has also become attracted the attention of the industry. WuXi PharmaTech's call the company, Head of Corporate Communications Miss Shao Ning said, "leadership is also responsible for publicizing United States, after the company's development plan listed only other leaders came back to answer, is not convenient to disclose. "
However, after Ge Li, WuXi PharmaTech's chairman, said in an interview the company the funds raised will be used for drug safety evaluation center construction, will also acquire a pharmaceutical and expansion.
As the largest pharmaceutical R & D outsourcing company, WuXi PharmaTech successful listing, and induced favorable for the capital market, which is the domestic pharmaceutical R & D outsourcing company is a good sign. Prior to the domestic pharmaceutical R & D outsourcing corporate finance means roughly self-financing, venture capital, private equity funds of funds and government support.
"Way to raise funds, including loans, venture capital and private equity funds, may be different for different development needs of business and take different measures." Kang Long Beijing Chemical Company General Manager's Office, said Ms Cheung head of foreign propaganda .
In fact, as with every new industry, drug research and development outsourcing in the early stages of development are subject to venture and private funding of all ages. But when the drug R & D outsourcing to a certain stage, when relatively large gap in funding requirements, venture and private support has been far from adequate, then need new financing. The listing is the most convenient means of financing is the most promising capital.
"Market is considered, but decided to look at the company's development." Zhang says. In addition, the company developed to a stage start generating their own profit, if the enterprises still do not have the mid-term hematopoietic function, basically it is difficult survived.
"However, no matter what your pursuit of the enterprise funds, without the possibility of listing if not to invest." Guo said the summer, while capital is intended to make money, and the other one should also have withdrawal mechanism.
"If the real size and strength and a team of companies, is worry about money, because the opportunities for outsourcing R & D capital on the business opportunities lead to the capture, essentially, the capital chasing investment enterprises." Guo Xia said.
By outsourcing for technology It is understood that the current global CRO market, the approximately 200 billion dollars, in 2010, this market will reach 30 billion U.S. dollars. As the cost, market, and many other advantages, many multinational companies targeting the China market, to China to outsource R & D, this trend to the domestic and foreign R & D enterprise package brings opportunities.
However, the advantages of the domestic pharmaceutical R & D outsourcing company's aim is not just for others to do awake, but has its own long-term plan, by the multinational pharmaceutical companies outsourcing services, savings from its own experience in drug development.
"Through the early co-operation with major foreign pharmaceutical manufacturers, drug development experience can be accumulated and accumulated technology and eventually develop new drugs with independent intellectual property products, it is our business are doing in one direction." Miss Zhang said.
Capital Blitz Drug Development Outsourcing Companies Take The Opportunity To Upgrade
